生物试剂
>
生化试剂
>
信号通路
> Batimastat sodium salt
加入收藏 取消收藏

Batimastat sodium salt  

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：5mg in glass bottle
溶解性：溶于DMSO(80mg/mL超声)
产品描述：基本信息 产品编号： B11395 产品名称： Batimastat sodium salt CAS: 130464-84-5   储存条件 粉末 -20℃ 四年     分子式： C23H30N3NaO4S2 溶于液体     分子量 499.62     化学名：      生物活性 产品描述 广谱的基质金属蛋白酶（MMPs）抑制剂。 靶点 IC50: 3nM (MMP-1), 4nM (MMP-2), 4nM (MMP-9), 6nM (MMP-7), 20nM (MMP-3) 体外研究 Batimastat (BB-94) is a potent matrix metalloproteinase inhibitor, exhibits an unexpected mode of binding. Batimastat inhibits gelatinases A and B with IC50 values of 4nM and 10nM, respectively. The IC50 with the structurally similar collagenase Ht-d is 6nM, which is comparable with values for MMP-1 (3nM), MMP-8 (10nM), and MMP-3 (20nM). CD30 shedding from the cell line Karpas299 can effectively be blocked by the hydroxamic acidbased metalloproteinase inhibitor Batimastat (BB-94, IC50=230nM) 体内研究 Intraperitoneal administration of Batimastat (BB-94) effectively blocks growth of human ovarian carcinoma xenografts and murine melanoma metastasis and delays the growth of primary tumors in an orthotopic model of human breast cancer without cytotoxicity and without affecting mRNA levels. Batimastat (BB-94) is a synthetic matrix metalloproteinase inhibitor that has shown antineoplastic and antiangiogenic activity in various tumor models. Treatment with Batimastat (60mg/kg i.p. every other day, for a total of eight injections) concomitantly with Cisplatin (4mg/kg i.v., every 7 days for a total of three injections) completely prevents growth and spread of both xenografts, and all animals are alive and healthy on day 200[4]. Kaplan-Meier analysis of survival (at 48 h) shows that animals treated with Batimastat (BB-94) have increased survival (95.2%) in comparison with controls (75%), and differences are almost statistically significant (p=0.064). Matrix density is analyzed in saline- or Batimastat (40mg/kg)-pretreated animals 4 h after E2 administration, the time point at which collagen density is observed to be at its lowest after hormone treatment   推荐实验方法(仅供参考) Animal Administration Mice Six-weeks-old female BALB/c mice are used. Mice are treated i.p. with Batimastat (BB-94, 50mg/kg) 1 h before and 24 h post-infection. Batimastat is suspended at 50mg/mL in DMSO and stored frozen at -20°C. Prior to use, it is diluted 20-fold in phosphate buffered saline (PBS), and 500μL are injected into animals. Control mice are injected with 500μL of 5% DMSO in PBS. Animals are sacrificed 48 h after i.c. challenge. Rats Female Sprague-Dawley rats are administered a single physiological dose of E2 (40μg/kg in a 0.9% NaCl, 0.4% EtOH vehicle) by intraperitoneal (i.p.) injection at the indicated time intervals prior to tissue collection at necropsy. This in vivo dose level of E2 has been shown to induce changes in uterine wet weight, tissue architecture, and gene expression characteristic of estrogen receptor activation. For all other experiments, animals are i.p. administered a single 40μg/kg bolus of E2 4 h prior to tissue harvest, while control animals receive vehicle only in all studies. Batimastat is administered i.p. at a dose level (40mg/kg in a 1× PBS, 0.1% Tween-20 vehicle) shown to be effective at inhibiting MMPs in vivo 4 h prior to E2 or saline control.
保存条件：-20℃

猜你喜欢